Division of Allergy/Immunology, Department of Pediatrics, Nationwide Children's Hospital, Columbus, Ohio, USA.
Curr Opin Allergy Clin Immunol. 2021 Apr 1;21(2):182-187. doi: 10.1097/ACI.0000000000000720.
In December 2019, a novel respiratory illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first described and named coronavirus disease 2019 (COVID-19). Although the knowledge base surrounding COVID-19 and SARS-CoV-2 has grown rapidly, significant gaps in our knowledge remain and inaccurate information continues to circulate. This review will discuss the interaction between asthma and COVID-19 to provide a comprehensive understanding based on the currently available published data.
Non-SARS human coronaviruses (HCoVs) are a significant cause of asthma exacerbations, but SARS-CoV-2 does not appear to exacerbate asthma. Data thus far strongly suggest that patients with asthma are at no increased risk of infection with SARS-CoV-2 or more severe disease if infected with COVID-19. Although the data are extremely limited on inhaled corticosteroids and biologic medications, there remain no data suggesting that these therapeutics positively or negatively impact the severity or outcome of COVID-19.
Data are rapidly evolving regarding COVID-19 and asthma. At this time, asthma does not appear to positively or negatively affect outcomes of COVID-19; however, it is imperative that practitioners keep abreast of the changing literature as we await a vaccine and control of this pandemic.
2019 年 12 月，一种新型呼吸道疾病由严重急性呼吸系统综合症冠状病毒 2（SARS-CoV-2）引起，并被首次描述和命名为 2019 年冠状病毒病（COVID-19）。虽然 COVID-19 和 SARS-CoV-2 的知识库迅速发展，但我们的知识仍存在重大空白，不准确的信息仍在继续传播。这篇综述将讨论哮喘与 COVID-19 之间的相互作用，以根据目前已发表的数据提供全面的理解。
非 SARS 人类冠状病毒（HCoVs）是哮喘加重的重要原因，但 SARS-CoV-2 似乎不会加重哮喘。迄今为止的数据强烈表明，如果感染 COVID-19，哮喘患者感染 SARS-CoV-2 或更严重疾病的风险没有增加。尽管关于吸入性皮质类固醇和生物药物的数据极其有限，但目前尚无数据表明这些治疗方法对 COVID-19 的严重程度或结果有积极或消极的影响。
关于 COVID-19 和哮喘的数据正在迅速发展。目前，哮喘似乎对 COVID-19 的结果没有积极或消极的影响；然而，随着我们等待疫苗和控制这一大流行病，从业者必须了解不断变化的文献，这一点至关重要。
